JP2008517045A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517045A5
JP2008517045A5 JP2007537367A JP2007537367A JP2008517045A5 JP 2008517045 A5 JP2008517045 A5 JP 2008517045A5 JP 2007537367 A JP2007537367 A JP 2007537367A JP 2007537367 A JP2007537367 A JP 2007537367A JP 2008517045 A5 JP2008517045 A5 JP 2008517045A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
derivative
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007537367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008517045A (ja
Filing date
Publication date
Priority claimed from GBGB0423273.2A external-priority patent/GB0423273D0/en
Application filed filed Critical
Publication of JP2008517045A publication Critical patent/JP2008517045A/ja
Publication of JP2008517045A5 publication Critical patent/JP2008517045A5/ja
Abandoned legal-status Critical Current

Links

JP2007537367A 2004-10-20 2005-10-13 癌の治療法 Abandoned JP2008517045A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0423273.2A GB0423273D0 (en) 2004-10-20 2004-10-20 Treatment of cancer
PCT/GB2005/003940 WO2006043031A2 (en) 2004-10-20 2005-10-13 Class iii slrp for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2008517045A JP2008517045A (ja) 2008-05-22
JP2008517045A5 true JP2008517045A5 (enExample) 2008-12-04

Family

ID=33484868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537367A Abandoned JP2008517045A (ja) 2004-10-20 2005-10-13 癌の治療法

Country Status (6)

Country Link
US (1) US20080096793A1 (enExample)
EP (1) EP1809314A2 (enExample)
JP (1) JP2008517045A (enExample)
CA (1) CA2626774A1 (enExample)
GB (1) GB0423273D0 (enExample)
WO (1) WO2006043031A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105784A1 (en) * 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation
CN102549436A (zh) 2009-07-27 2012-07-04 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
DE4445630A1 (de) * 1994-12-21 1996-06-27 Forssmann Wolf Georg Humane zirkulierende Peptidfragmente 20-92 und 23-74 des Precursor des Osteoinduktiven Faktors kurz: OIF-20-92 und OIF 23-74
AU5593398A (en) * 1996-12-05 1998-06-29 Alcon Laboratories, Inc. The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
WO2000068264A2 (en) * 1999-05-10 2000-11-16 The Texas A & M University System A peptide inhibitor of fibrinogen blood clotting
US7304137B2 (en) * 2001-12-13 2007-12-04 The Texas A & M University System Nucleotide and amino acid sequences of asporins
WO2004105784A1 (en) * 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation

Similar Documents

Publication Publication Date Title
MX2013001749A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
JP2007526248A5 (enExample)
JP2009500431A5 (enExample)
EA200900667A1 (ru) Селективные аналоги глюкагонподобного пептида-2 (glp-2)
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
JP2011521897A5 (enExample)
JP2014513952A5 (enExample)
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
JP2011516501A5 (enExample)
JP2010524968A5 (enExample)
JP2007530584A5 (enExample)
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
JP2010536714A5 (enExample)
WO2008031016A3 (en) Heterocyclic ligands for integrin imaging and therapy
WO2020103961A9 (zh) 一种脑部肿瘤靶向肽及其应用
WO2002100885A3 (en) A penta- or tetrapeptide binding to somatostatin receptors and the use of the same
AR069767A1 (es) Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa)
JP2008517045A5 (enExample)
MX2008011473A (es) El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.
JP2010537623A5 (enExample)
JP2009516719A5 (enExample)
EP4282490A3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
JP2007502855A5 (enExample)
JP2008502323A5 (enExample)
EA200801670A1 (ru) Комбинированная противораковая терапия с перфузией изолированного органа